Last updated: May 13, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT06904066 | 1 | Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies | Patient-specific neoantigen TCRs -- autologous T cell receptor (TCR) transduced T cells |
| NCT06934044 | 1 | A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma | FcRH5 -- bispecific antibody |
| NCT07116616 | 1, 2 | A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma | Unknown mechanism |
| NCT06152575 | 3 | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | BCMA + SLAMF7 -- bispecific antibody (Elranatamab + Elotuzumab) |
| NCT06948084 | 2 | Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse | CD38 + BCMA -- bispecific antibody (teclistamab) + monoclonal antibody (daratumumab) |
| Sponsor | Recruiting trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 23 |
| Janssen Research & Development, LLC | 13 |
| Memorial Sloan Kettering Cancer Center | 12 |
| Regeneron Pharmaceuticals | 11 |
| Washington University School of Medicine | 10 |
Countries with the most active trial sites for multiple myeloma. A multi-site trial is counted once per country.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Jul 2026 | NCT07479979 | Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma | XPO1 -- selective inhibitor of nuclear export (selinexor); Proteasome -- proteasome inhibitor (carfilzomib); CD38 -- monoclonal antibody (isatuximab) |
| Jul 2026 | NCT07221032 | FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma | NKG2D -- CAR-T + CD38 -- monoclonal antibody (daratumumab) |
| Jun 26, 2026 | NCT07463807 | Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment | BCMA + CD3 -- bispecific antibody (teclistamab); Cereblon modulator (pomalidomide); Proteasome inhibitor (carfilzomib) |
| Jun 1, 2026 | NCT07458659 | Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma | BCMA -- CAR-T cell therapy |
| Jun 1, 2026 | NCT07407010 | BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM | BCMA + CD3 -- bispecific antibody |
| Jun 1, 2026 | NCT04579523 | ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma | CD38 -- radioimmunotherapy (211At-OKT10-B10) |
| Jun 1, 2026 | NCT07558915 | A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | CD38 -- antibody-drug conjugate (ADC) |
| May 31, 2026 | NCT07200089 | Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) | IL-7 receptor -- cytokine receptor agonist (NT-I7) |
Want trials matched to a specific patient profile?
Enter biomarkers, stage, and prior treatments — get ranked trial matches with eligibility breakdown in minutes.
Find Matching TrialsSource: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.